Gabapentin versus Ropinirole in the Treatment of Idiopathic Restless Legs SyndromeHappe S. · Sauter C. · Klösch G. · Saletu B. · Zeitlhofer J.
Departments of aClinical Neurology and bPsychiatry, University of Vienna, Vienna, Austria; cDepartment of Clinical Neurophysiology, University of Göttingen, Göttingen, Germany
Dopaminergic agents such as ropinirole are the drugs of first choice in treating restless legs syndrome (RLS). Recently, gabapentin, a structural analogue of γ-aminobutyric acid, has also been shown to improve sensorimotor symptoms in RLS. Therefore, the tolerability and efficacy of randomized treatment with either gabapentin or ropinirole in patients with idiopathic RLS was evaluated in this 4-week open clinical trial. Patients with idiopathic RLS were treated with either 300 mg of gabapentin (n = 8) or 0.5 mg of ropinirole (n = 8) as the initial dose, and the dose was up-titrated until relief of symptoms was achieved (gabapentin mean dosage 800 ± 397 mg, range 300–1,200 mg; ropinirole mean dosage 0.78 ± 0.47 mg, range 0.25–1.50 mg). In both groups, International Restless Legs Syndrome Study Group questionnaire scores improved significantly (p ≤ 0.018), whereas the scores of the Epworth sleepiness scale remained unchanged within normal limits. Polysomnographic data showed a reduction of periodic leg movements during sleep (PLMS; p < 0.03) and PLMS index (p < 0.02) in both groups. Side effects were only mild and mostly transient. After 6–10 months of follow-up, in most patients, RLS symptoms were still improved. We conclude that gabapentin and ropinirole provide a similarly well-tolerated and effective treatment of PLMS and sensorimotor symptoms in patients with idiopathic RLS.
Svenja Happe, MD
Department of Clinical Neurophysiology, University of Göttingen
DE–37075 Göttingen (Germany)
Tel. +49 551 398453, Fax +49 551 3912651, E-Mail email@example.com
Number of Print Pages : 5
Number of Figures : 0, Number of Tables : 2, Number of References : 25
Founded 1975 by J. Mendlewicz (Brussels)
Official Journal of the International Pharmaco-EEG Society (IPEG)
Vol. 48, No. 2, Year 2003 (Cover Date: Released September 2003)
Journal Editor: P. Netter, Giessen; J. Mendlewicz, Brussels; B. Saletu, Vienna
ISSN: 0302–282X (print), 1423–0224 (Online)
For additional information: http://www.karger.com/nps